Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1953 1
1955 1
1960 1
1963 2
1979 1
1980 1
1985 1
1986 1
1988 1
1989 4
1990 2
1991 2
1992 2
1994 1
1998 1
1999 1
2001 1
2003 3
2004 1
2005 2
2006 4
2007 5
2008 3
2009 6
2010 8
2011 11
2012 15
2013 10
2014 10
2015 12
2016 13
2017 11
2018 14
2019 19
2020 17
2021 21
2022 19
2023 9
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Among authors: gallardo c. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Among authors: gallardo c. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Shitara K, et al. Among authors: gallardo c. Nature. 2022 Mar;603(7903):942-948. doi: 10.1038/s41586-022-04508-4. Epub 2022 Mar 23. Nature. 2022. PMID: 35322232 Free PMC article. Clinical Trial.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, Kim SW, Borghaei H, O'Byrne KJ, Hellmann MD, Memaj A, Nathan FE, Bushong J, Tran P, Brahmer JR, Reck M. Paz-Ares LG, et al. Among authors: gallardo c. J Thorac Oncol. 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010. Epub 2021 Oct 12. J Thorac Oncol. 2022. PMID: 34648948 Free article. Clinical Trial.
Neutrophil-Erythrocyte Rosettes in COVID-19.
Fan BE, Leong JQW, Leung BPL, Ng WY, Lim WSL, Wong WYK, Lim WY, Chen SPC, Yap SYR, Tan GB, Chow M, Mucheli SS, Kuperan P, Gallardo CA. Fan BE, et al. Among authors: gallardo ca. Am J Hematol. 2023 Jan;98(1):220-221. doi: 10.1002/ajh.26637. Epub 2022 Jun 29. Am J Hematol. 2023. PMID: 35726451 Free PMC article. No abstract available.
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. Janjigian YY, et al. Among authors: gallardo c. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. doi: 10.1200/JCO.23.01601. Epub 2024 Feb 21. J Clin Oncol. 2024. PMID: 38382001 Free PMC article. Clinical Trial.
Single-agent daratumumab for refractory POEMS syndrome.
Tiew HW, Sampath VS, Gallardo CA, Christopher D, Chan SSW, Wong SW, Tso ACY, Lee LK, Fan BE. Tiew HW, et al. Among authors: gallardo ca. Am J Hematol. 2022 Jun 1;97(6):E189-E191. doi: 10.1002/ajh.26517. Epub 2022 Mar 11. Am J Hematol. 2022. PMID: 35253931 Free article. No abstract available.
Gaps in African swine fever: Analysis and priorities.
Arias M, Jurado C, Gallardo C, Fernández-Pinero J, Sánchez-Vizcaíno JM. Arias M, et al. Among authors: gallardo c. Transbound Emerg Dis. 2018 May;65 Suppl 1:235-247. doi: 10.1111/tbed.12695. Epub 2017 Sep 22. Transbound Emerg Dis. 2018. PMID: 28941208 Review.
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, Pauwels P, Mahave M. Rolfo C, et al. Among authors: gallardo cd. Adv Exp Med Biol. 2017;995:97-125. doi: 10.1007/978-3-319-53156-4_5. Adv Exp Med Biol. 2017. PMID: 28321814 Review.
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
Cescon DW, Schmid P, Rugo HS, Im SA, Md Yusof M, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Haiderali A, Zhou X, Guo Z, Nguyen AM, Cortes J. Cescon DW, et al. Among authors: gallardo c. J Natl Cancer Inst. 2024 May 8;116(5):717-727. doi: 10.1093/jnci/djad240. J Natl Cancer Inst. 2024. PMID: 38070159 Clinical Trial.
208 results